SaxendaCare® is sponsored by Novo Nordisk Pharmaceuticals Pty Ltd (Novo Nordisk) and is managed and administered by a third party service provider nominated by Novo Nordisk from time-to-time.
Your use of this Website, or any other services or content provided through the Website, shall be deemed to constitute your consent to be legally bound by the terms and conditions of the Agreement, which shall be enforceable in the same way as if you had signed the Agreement. If you are not willing to accept the terms and conditions of the Agreement, we ask that you not access or use the Website or post or submit any materials on it.
Information Disclaimer: The information contained on this Website including any advice and/or recommendations is intended solely as a general educational aid. It is not intended as medical or healthcare advice or to be used for medical diagnosis or treatment. Always seek the advice of a doctor or other qualified healthcare professional regarding any medical condition and before starting any new treatment. Your use of the Website is subject to the additional disclaimers and caveats that may appear throughout the website.
Neither Novo Nordisk nor its third party service provider assume any responsibility for, and to the maximum extent permitted by applicable law exclude any liability to you for, any consequences relating directly or indirectly to any action or inaction you take based on the information, services or other material on the Website. While we strive to keep the information on the Website accurate, complete, and up to date, we do not give any assurances, and will not be responsible for any damage or loss related to the inaccuracy, incompleteness, or lack of timeliness of the information on the Website.
Website Intended Audience: This Website is intended for and directed to residents of Australia who have been prescribed a Novo Nordisk pharmaceutical product. Only those patients who are over 18 years of age or prescribed the Saxenda® for its approved indication can access SaxendaCare®. Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:
≥30 kg/m2 (obese) or
≥27 kg/m2 to 30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.
Patients who are prescribed a Novo Nordisk therapeutic good by their healthcare professional are eligible to enrol as a participant into the SaxendaCare® Patient Support Program (the Program).
Not all therapeutic goods distributed by Novo Nordisk in Australia will have a patient support program.
Enrolment into the Program does not replace any advice provided to a patient by their doctor and/or healthcare professional including any information related to the treatment which you have been prescribed.
Please speak with a doctor and/or healthcare professional if you have any questions or concerns about your treatment and/or your condition.
The range of activities and services offered as part of the Program is specific to your healthcare needs and will vary depending on your medical history, your treatment, and/or your condition. Participation in the Program is designed to complement and support the instructions of your healthcare professional. The duration of your enrolment in the Program will be dependent upon your continued treatment with a Novo Nordisk therapeutic good.
All activities and services offered under the Program are optional, allowing you to opt into all or a selection of the available services. A list of the available services is set out under section 14 below.
Services: The Program may offer all or some of the following services:
Allied Health Support Services
General Health and Wellness Information
Online and Mobile Platforms
Online Chat Services
You may opt out from receiving communications from Novo Nordisk and/or its third party service provider, by following the prompts within the communications sent to you or by opting out of the Program by calling 1300 079 839 or email email@example.com.
Data Sharing with Novo Nordisk: Any self-reported safety information (including adverse events, special situations, and product complaints) that may arise in connection with a Novo Nordisk therapeutic good will be reported to Novo Nordisk to ensure regulatory reporting compliance with the relevant regulatory body and/or in accordance with Novo Nordisk’s safety information reporting processes. Novo Nordisk may use your personal information to contact you and/or your healthcare professional to obtain additional information relating to the safety event or safety information.
(a) Safety Information will be recorded in Novo Nordisk’s global safety database and will be analysed and regularly assessed to identify overall patterns;
(b) Novo Nordisk may share personal data related to Safety Information with health authorities, its parent company Novo Nordisk A/S and other entities (e.g., its affiliates in other countries), partner companies that assist Novo Nordisk (e.g. license partners, consultants, IT service providers), other pharmaceutical companies if the safety information is considered related to their product(s), in accordance with applicable law; and
(c) Novo Nordisk will store personal data related to Safety Information in accordance with Novo Nordisk's retention policies and applicable law. Novo Nordisk may also grant access to information technology services, for the purpose of system administration only.
De-identified information relating to a patient’s participation in a Program may be collated into a report for Novo Nordisk. Novo Nordisk may use this information to:
help develop and evaluate the therapeutic treatment(s), the Program, services and materials;
enable research, including future scientific research and publications to help future patients;
promote awareness of the Program.
Electronic Communications: The information communicated on the Website constitutes an electronic communication. When you communicate with us through the Website or via other forms of electronic media, such as email, you are communicating with us electronically. You agree that we may communicate electronically, subject to applicable privacy laws, and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communications.
A prescribing physician or healthcare profession enrolling a patient into the Program consents to their personal information being used in connection with the Program including but not limited to general contact or information updates regarding the Program and patient-related updates.
Storage of User Content: We may impose a maximum amount of storage for User Content on the Website. We are note responsible for any loss or harm you may suffer as a result of any deletion or failure to store any messages, communications or other User Content associated with maintaining the maximum amount of storage.
Warranties and Liabilities: Warranties and Liabilities: Information on this Website is provided on an “as is” and “as available” basis. While Novo Nordisk uses reasonable efforts to ensure that the information is accurate and up to date, the information may contain technical inaccuracies or errors. Novo Nordisk reserves the right to make changes, corrections and/or improvements to the information, and to the products and Program described, at any time and without notice. Novo Nordisk assumes no liability or responsibility for any errors or omissions regarding the content within the Website. Novo Nordisk provides no warranties about the completeness or accuracy of the information on this site or its possible uses. Neither Novo Nordisk, nor any of its affiliates, directors, officers, employees, nor any other party involved in the creation of the content within this Website, or the third party service provider managing the Website, shall be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of access to, use of or inability to use this Website, or any errors or omissions in the content of the Website. Novo Nordisk also assumes no responsibility, and will not be liable for any damages to, or viruses that may infect your computer equipment or other device you use to access this Website.
For any SaxendaCare® Patient Support Program questions please contact the SaxendaCare® Support Team:
Phone: 1300 079 839
For any product related enquiries, please contact Novo Nordisk Customer Care:
Phone: 1800 668 626
Governing Law: This Agreement is governed by and must be construed according to the law applying in New South Wales.
Survival: All clauses of this Agreement will be deemed to survive any termination of this Agreement.
1. that the information you are about to be referred to may not comply with the Australian regulatory environment and that readers should refer to the CMI for products to fully understand the terms of a product’s registration in Australia;
2. that the intent of providing this material is informational and not as advice; and
3. any information provided by this source should be discussed with the reader’s healthcare professional and does not replace their advice